The PERL Team

The PERL team is a group of doctors and researchers who are committed to helping people with type 1 diabetes. The PERL Consortium is led by Dr. Alessandro Doria and Dr. Michael Mauer. Site Directors from 13 hospitals and institutions throughout the United States, Canada and Denmark lead their local teams of study coordinators. Other important groups involved in the study include a Data Coordinating Center led by Drs. Andrzej Galecki and Cathie Spino, and a Central Laboratory led by Dr. Amy Karger.

Learn more about team members below.

Study Chairs

Alessandro Doria, MD, PhD, MPH

Joslin Diabetes Center
Harvard Medical School
Boston, MA
Website

Dr. Doria received his medical degree and his doctorate in metabolism and endocrinology from the University of Padua in Italy. After moving to the US in 1990, he has established himself as one of the leading researchers in the genetics and epidemiology of diabetic complications, discovering several genes that modulate cardiovascular risk in diabetes. He was among the investigators who identified serum uric acid as a risk factor for kidney complications and is now the co-principal investigator of the PERL clinical trial investigating the serum uric-lowering drug allopurinol as a potential treatment to prevent early kidney function loss in diabetes.

Dr. Doria is currently a Senior Investigator at the Joslin Diabetes Center in Boston as well as an Associate Professor of Medicine at Harvard Medical School and an Associate Professor in the Department of Epidemiology at the Harvard School of Public Health.

Continuously funded by the National Institutes of Health since 1998, he has published more than 100 original papers in scientific journals including JAMA, New England Journal of Medicine, Nature Genetics, PNAS, and others. He regularly serves as a reviewer for the NIH, research agencies of several European countries, and international journals. He was a member of the Editorial Board of Diabetes and currently serves as an Associate Editor for Diabetologia.

In 2006 and 2010, he was awarded the Michaela Modan Memorial Award by the American Diabetes Association.

 

S. Michael Mauer, MD


University of Minnesota Medical School

Minneapolis, MN
Website

For more than 40 years Dr. Mauer's primary research focus has been the kidney disease of diabetes [diabetic nephropathy], this the leading cause of kidney failure in the Western world. Dr Mauer has published more than 150 research articles and 50 book chapters on diabetic nephropathy. He was largely responsible for describing the relationships of the kidney structural changes to kidney functional loss in diabetic nephropathy.

In breakthrough studies, he was able to demonstrate remarkable reversibility of diabetic nephropathy structural injury to the kidney following cure of diabetes with pancreas transplantation. For many years he has worked to unravel the cellular, molecular and genetic basis of the disorder. He has also helped to shape national guidelines for diabetic nephropathy treatment. Dr. Mauer has previously successfully directed a large NIH funded clinical trial aimed at primary prevention of diabetic nephropathy. He was Principle Investigator [PI] of a National Institutes of Health [NIH] grant to discover early urine and blood predictors of diabetic nephropathy risk. He is currently co-PI of PERL, an NIH sponsored early treatment trial to slow or prevent early renal function loss in diabetic nephropathy.

For more than 4 decades his research work has been supported by the NIH, the Juvenile Diabetes Foundation International and the American Diabetes Association. In recognition of his research contributions he has been appointed to the University of Minnesota Academic Health Center Academy of Academic Excellence.




PERL Sites

Colorado
Barbara Davis Center for Diabetes
University of Denver – Anschutz Medical Campus
Aurora, CO
Sarit Polsky, MD – Site Director

Kaiser Permanente Colorado Institute for Health Research
Midtown Medical Offices
Denver, CO
Emily Schroeder, MD, PhD – Site Director

Georgia
Atlanta Diabetes Institute
Atlanta, GA
Bruce Bode, MD – Site Director

Emory University
Diabetes & Endocrinology Grady Health System
Atlanta, GA
Guillermo E. Umpierrez, MD, CDE - Site Director

Atlanta VA Medical Center
Grady Memorial Hospital/Emory University
Decatur, GA
Darin Olson, MD, PhD - Site Director

Illinois
Northwestern University Feinberg School of Medicine
Division of Endocrinology, Metabolism and Molecular Medicine
Chicago, IL
Mark Molitch, MD – Site Director

Massachusetts
Joslin Diabetes Center
Boston, MA
Alison Goldfine, MD – Site Director

Massachusetts General Hospital
Diabetes Center
Boston, MA
Enrico Cagliero, MD - Site Director

University of Massachusetts
UMass Memorial Health Care
Worchester, MA
Michael J. Thompson, MD – Site Director

Michigan
Division of Metabolism, Endocrinology and Diabetes
Michigan Comprehensive Diabetes Center
University of Michigan
Ann Arbor, MI
Rodica Pop-Busui, MD, PhD – Site Director

Henry Ford Medical Center
Division of Endocrinology, Diabetes, Bone & Mineral Disorders
Clinical Research & Education
Detroit, MI
Arti Bhan, MD – Site Director

Ann Arbor VA Medical Center
University of Michigan
Metabolism, Endocrinology and Diabetes & Department of Nephrology
Ann Arbor, MI
Lynn Ang, MD - Co-Site Director
Rachel Perlman, MD - Co-Site Director

Minnesota
Minneapolis VA Medical Center
Minneapolis, MN
Douglas DeCarolis, Pharm.D., BCPS – Site Director

University of Minnesota
Division of Endocrinology and Diabetes
Department of Medicine
Minneapolis, MN
Maria Luiza Caramori, MD, PhD – Site Director

University of Minnesota
Nephrology Studies
Minneapolis, MN
Yelena Slinin, MD – Site Director

Missouri
Washington University School of Medicine
St. Louis, MO
Janet McGill, MD – Site Director

New York
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, NY
Jill Crandall, MD – Site Director

Albert Einstein College of Medicine
ICAHN School of Medicine at Mount Sinai
New York, NY
Carol Levy, MD - Site Director

Jacobi Medical Center
Bronx, NY
Ulrich Schubart, MD - Site Director

SUNY Upstate Medical University
Institute for Human Performance
Syracuse, NY
Ruth Weinstock, MD, PhD - Site Director

Winthrop-University Hospital
Clinical Trials Center
Mineola, NY
Shayan Shirazian, MD - Site Director

Weill Cornell Medical Center
Department of Medicine/Division of Endocrinology
New York, NY
Naina Sinha Gregory, MD - Site Director

Texas
University of Texas Southwestern Medical Center at Dallas
Dallas, TX
Ildiko Lingvay, MD – Site Director

Washington
Providence Sacred Heart Medical Center
University of Washington Medical Center
Spokane, WA
Katherine R. Tuttle, MD – Site Director

University of Washington Medical Center
Endocrine and Diabetes Care Center
Seattle, WA
Irl B. Hirsch, MD - Site Director

Virginia Mason Medical Center
Benaroya Research Institute
Seattle, WA
Grace Lee, MD – Site Director

Wisconsin
Gundersen Health System
La Crosse, WI
Mary K. Frohnauer, MD – Site Director

Alberta (Canada)
Division of Endocrinology, Dept. of Medicine
University of Calgary
Calgary, AB, Canada
Ron Sigal, MD, MPH, FRCPC - Site Director

Alberta Diabetes Institute
Li Ka Shing Centre for Health Research Innovation
Edmonton, AB, Canada
Peter Senior, MD - Site Director

British Columbia (Canada)
BC Diabetes
Vancouver, BC, Canada
Thomas G. Elliott, MD – Site Director

Ontario (Canada)
University of Toronto
Mt. Sinai Hospital
Toronto, ON, Canada
Bruce Perkins, MD - Site Director

LMC Diabetes & Endocrinology
Toronto, ON, Canada
Ronnie Aronson, MD - Site Director

LMC Diabetes & Endocrinology
Thornhill, ON, Canada
Ronnie Aronson, MD - Site Director

Denmark
Steno Diabetes Center
Copenhagen, Denmark
Peter Rossing, Professor, MD, DMSc - Site Director


 

 

 

To learn more about PERL, click on the tabs above.

return to top